The following stories appear in full on today's Vidyya Medical News Service Web site.
Pfizer Inc said yesterday that the US Food and Drug Administration (FDA) has approved ziprasidone HCl capsules, a novel antipsychotic medicine for treatment of schizophrenia. Discovered and developed by Pfizer, ziprasidone is a serotonin and dopamine antagonist that is effective across its dose range in treating the positive and negative symptoms associated with schizophrenia.
For more information: FDA Approves Pfizer Schizophrenia Medicine - Ziprasidone
Enterix Inc. announced today that its new colorectal cancer screening test, !nSure(TM), has received premarket clearance from the US Food and Drug Administration. !nSure(TM) is an immunochemical fecal occult blood test (FOBT) that detects hidden (occult) blood that originates in the lower intestine, which might indicate a developing cancer.
For more information: FDA Approves New Colorectal Cancer Screening Test
Cancer of the colon is a highly treatable and often curable disease when
localized to the bowel. It is the second most frequently diagnosed malignancy
in the United States as well as the second most common cause of cancer death.
Surgery is the primary form of treatment and results in cure in approximately
50% of patients. Recurrence following surgery is a major problem and often is
the ultimate cause of death. The prognosis of colon cancer is clearly related
to the degree of penetration of the tumor through the bowel wall and the
presence or absence of nodal involvement.
For more information: Colon Cancer: Treatment Information For Health Professionals
Scientists who tracked the health of 420,000
Danish cell phone users found no sign the devices cause cancer, the
biggest study yet to provide reassurance about the phones' safety--
but one that won't completely settle the controversy.
For more information: Study Of 420,000 Danish Cell Phone Users Finds No Evidence Of Cancer
Men with prostate cancer that has spread to the bones may live longer if given a combination of chemotherapy and a bone-targeted radiation drug, according to research reported in the 03 February 2001, issue of the Lancet. While most men survive five years or more with early prostate cancer, those diagnosed at later stages don't live nearly as long. In fact, in cases where prostate cancer has spread to the bones and is resistant to standard hormonal therapy, the average life expectancy is nine months.
For more information: Patients With Advanced Prostate Cancer May Benefit From Bone-Targeted Drug
Today's Vidyya articles are:
As always, we hope you enjoy the issue.